0
0
Hiroshima, Japan—May 27, 2025
A new study published in the European Journal of Human Genetics is challenging the way Japan—and potentially other countries—assesses the “seriousness” of genetic conditions, urging policymakers to give greater weight to patient experiences alongside traditional medical criteria.
Rigid Criteria Under Scrutiny
Japan has long maintained strict guidelines for preimplantation genetic testing (PGT-M), allowing the procedure for only 17 genetic conditions as approved by the Japanese Society of Obstetrics and Gynecology. These decisions have historically relied on narrow medical definitions, often overlooking the nuanced realities faced by patients and their families.
But recent cases, such as the delayed recognition of retinoblastoma as a “serious” disorder after years of advocacy, have spotlighted the limitations of this approach. “The seriousness of genetic disorders has traditionally been assessed using narrow medical criteria,” explained Shizuko Takahashi, a research fellow at the National University of Singapore. “This limits access to important reproductive options for many families.”
Lived Experience Shifts Perspectives
The study, led by researchers at Hiroshima University, drew on a framework proposed by Erika Kleiderman and colleagues, emphasizing the importance of incorporating stakeholder values and lived experiences into assessments of genetic conditions.
During a stakeholder dialogue event in Hiroshima, participants’ perceptions of “seriousness” were measured before and after hearing firsthand accounts from individuals with hereditary cancer, including those affected by retinoblastoma and BRCA2 mutations.
The results were striking:
-
Before patient testimonies: 66% of participants said they would consider PGT-M if faced with hereditary cancer, and 89% felt patients should be informed about the option at diagnosis.
-
After patient testimonies: There was a significant decrease in the number of participants who viewed PGT-M primarily as a public health tool to reduce societal burden (p = 0.005). Instead, there was a marked increase in support for individual reproductive autonomy. Favorable attitudes toward marriage, pregnancy, and family planning with PGT-M rose from 54% to 71%.
“Lived experiences profoundly shape how people understand the ‘seriousness’ of hereditary cancer,” said Rie Iizuka, assistant professor at Hiroshima University. “These stories can shift perceptions of genetic testing from being about societal burden to being about individual choice and autonomy.”
Implications for Policy and Ethics
The study underscores the urgent need to include patient voices in shaping ethical frameworks and policy decisions around genetic testing. The researchers acknowledge limitations, including a small and specialized participant pool, but hope future research will broaden the conversation.
“Our aim is to provide empirical support for the idea that assessments of the seriousness of genetic conditions should meaningfully incorporate stakeholders’ lived experiences,” said Tsutomu Sawai, professor of ethics at Hiroshima University.
Looking Ahead
As genetic testing technologies advance and become more accessible, the debate over how to define “seriousness” in genetic conditions is likely to intensify. This new research suggests that listening to those most affected—patients and their families—may be key to crafting compassionate and effective policies.
Disclaimer:
This article summarizes findings from a recent study and is intended for informational purposes only. It does not constitute medical advice. For personal health decisions, please consult a qualified healthcare professional. The study referenced is subject to limitations, including sample size and participant selection, and further research is ongoing. For more details, see the original publication: Shizuko Takahashi et al, European Journal of Human Genetics (2025), DOI: 10.1038/s41431-025-01829-6.
Citations:
